HS
URGN icon

HighVista Strategies’s UroGen Pharma URGN Stock Holding History

HighVista Strategies’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$919K Sell
24,968
-1,542
-6% -$41.8K 0.21% 126
2026
Q1 		$477K Sell
26,510
-1,495
-5% -$30K 0.13% 149
2025
Q4 		$656K Sell
28,005
-3,881
-12% -$84.2K 0.17% 130
2025
Q3 		$636K Buy
+31,886
New +$573K 0.16% 137
2024
Q4 		– Sell
-38,566
Closed -$490K – 167
2024
Q3 		$490K Buy
+38,566
New +$572K 0.17% 131

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

HighVista Strategies's URGN Position: Q2 2026 in Review

HighVista Strategies reduced its UroGen Pharma (URGN) stake by 5.8% in Q2 2026, selling an estimated $41.8K and leaving 24,968 shares worth $919K. The position accounts for 0.21% of the portfolio, ranked #126.

HighVista Strategies first reported a position in URGN in Q3 2024 and has held it in 5 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • HighVista Strategies held 24,968 shares of UroGen Pharma worth $919K as of Q2 2026.
  • HighVista Strategies sold 1,542 UroGen Pharma shares in Q2 2026, an estimated $41.8K.
  • UroGen Pharma made up 0.21% of HighVista Strategies's portfolio in Q2 2026, its #126 holding.
  • HighVista Strategies first reported a position in UroGen Pharma in Q3 2024 and has held it in 5 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.